Navigation Links
Arena Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
Date:1/6/2011

al and commercialization of lorcaserin; the Eisai collaboration and potential activities thereunder; and Arena's focus, goals, strategy, research and development programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: the risk that regulatory authorities may not find data and other information related to Arena's clinical trials and other studies meet safety or efficacy requirements or are otherwise sufficient for regulatory approval; the timing of regulatory review and approval is uncertain; Arena's response to the complete response letter for the lorcaserin NDA may not be submitted in a timely manner or the information provided in such response may not satisfy the FDA; the FDA may request other information prior to or after Arena resubmits the lorcaserin NDA or approval of the lorcaserin NDA; unexpected or unfavorable new data; risks related to commercializing new products; Arena's ability to obtain and defend its patents; the timing, success and cost of Arena's research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner Arena or others expect or at all; Arena's ability to obtain adequate funds; risks related to relying on collaborative agreements; the timing and receipt of payments and fees, if any, from collaborators; and satisfactory resolution of pending and any future litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statemen
'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
7. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
8. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
9. Critical Pharmaceuticals Enter Sustained Release hGH Arena
10. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)...  CVS Health is thanking its 26,000 pharmacists during ... the way health care is delivered to increase access, ... pharmacies, mail service pharmacies and specialty pharmacies nationwide.  ... to CVS Health to reflect our broader health care ... to shape the future of health," said Larry ...
(Date:9/30/2014)... 30, 2014 This report analyzes the worldwide markets ... Product Categories: Enteral Feeding Pumps, Nasogastric Tubes, and Others. ... Canada, Japan , Europe ... , and Rest of World. Annual estimates and forecasts ... six-year historic analysis is provided for these markets. ...
(Date:9/30/2014)... , Sept. 30, 2014  Tasly Pharmaceuticals, Inc., ... modernize medicine, announced today the launch of Deepure. ... developed to address men and women concerned with ... vibrant into old age while helping keep their ... condition-specific, whole-food and herb-based formulas, namely, ProHeart PLUS, ...
Breaking Medicine Technology:CVS Health Thanking its Pharmacists during American Pharmacists Month for Helping People on Their Path to Better Health 2CVS Health Thanking its Pharmacists during American Pharmacists Month for Helping People on Their Path to Better Health 3Global Enteral Feeding Devices Industry 2Global Enteral Feeding Devices Industry 3Global Enteral Feeding Devices Industry 4Global Enteral Feeding Devices Industry 5Global Enteral Feeding Devices Industry 6Global Enteral Feeding Devices Industry 7Global Enteral Feeding Devices Industry 8Global Enteral Feeding Devices Industry 9Global Enteral Feeding Devices Industry 10Global Enteral Feeding Devices Industry 11Global Enteral Feeding Devices Industry 12Global Enteral Feeding Devices Industry 13Global Enteral Feeding Devices Industry 14Global Enteral Feeding Devices Industry 15Global Enteral Feeding Devices Industry 16Global Enteral Feeding Devices Industry 17Global Enteral Feeding Devices Industry 18Global Enteral Feeding Devices Industry 19
... Inc. (Nasdaq: DCTH ) announced today that it has ... common stock at $3.60 per share, or $30.6 million, pursuant ... the Company has granted the underwriters of the offering an ... primary stock to cover over-allotments. The offering is expected ...
... NEW YORK, Nov. 12 Reportlinker.com announces ... available in its catalogue. , ... to 2015 , ... Market Analysis & Forecasts to 2015 , ...
Cached Medicine Technology:Delcath Systems, Inc. Prices $30.6 Million Stock Offering 2Reportlinker Adds US Orthopedic Devices Market Analysis & Forecasts to 2015 2Reportlinker Adds US Orthopedic Devices Market Analysis & Forecasts to 2015 3Reportlinker Adds US Orthopedic Devices Market Analysis & Forecasts to 2015 4Reportlinker Adds US Orthopedic Devices Market Analysis & Forecasts to 2015 5Reportlinker Adds US Orthopedic Devices Market Analysis & Forecasts to 2015 6Reportlinker Adds US Orthopedic Devices Market Analysis & Forecasts to 2015 7Reportlinker Adds US Orthopedic Devices Market Analysis & Forecasts to 2015 8Reportlinker Adds US Orthopedic Devices Market Analysis & Forecasts to 2015 9Reportlinker Adds US Orthopedic Devices Market Analysis & Forecasts to 2015 10Reportlinker Adds US Orthopedic Devices Market Analysis & Forecasts to 2015 11Reportlinker Adds US Orthopedic Devices Market Analysis & Forecasts to 2015 12Reportlinker Adds US Orthopedic Devices Market Analysis & Forecasts to 2015 13Reportlinker Adds US Orthopedic Devices Market Analysis & Forecasts to 2015 14Reportlinker Adds US Orthopedic Devices Market Analysis & Forecasts to 2015 15Reportlinker Adds US Orthopedic Devices Market Analysis & Forecasts to 2015 16Reportlinker Adds US Orthopedic Devices Market Analysis & Forecasts to 2015 17
(Date:10/1/2014)... October 01, 2014 Phoseon Technology, the ... continues to expand the business worldwide. This rapid growth ... additional capacity for manufacturing efforts. The company has experienced ... five years and expects this growth to continue in ... technology gains worldwide adoption. , “We are very ...
(Date:10/1/2014)... Beverly Hills licensed Clinical Psychologist and nationally ... years of private practice in her Beverly Hills office ... greater joy and fulfillment in their relationships. Dr. Mojas ... suggestions for anyone who suspects they are in a ... or not, it’s not always easy to know when ...
(Date:10/1/2014)... October 01, 2014 Anti Aging Clinic ... skin rejuvenating destination of choice, is announcing a discounted ... through to December. , “We’re doing this because we ... to our top skin clinic in Toronto,” says Dr. ... so much at Anti Aging Clinic, including laser facials, ...
(Date:10/1/2014)... October is national Breast Cancer Awareness Month—an ... while raising money for breast cancer research. Pelican Water ... in the effort to find a cure. ... of having access to clean, healthy water. Research has ... certain forms of cancer. , The Problem of ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Generic drug ... retail generics increasing in price in the last 12 ... Inc.’s (AIS) Drug Benefit News (DBN) interviewed a plan ... means for pharmacies and health plans. , “When ... rising generic acquisition costs, these cost increases squeeze pharmacies’ ...
Breaking Medicine News(10 mins):Health News:Phoseon Technology Continues to Drive Growth Worldwide 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 3Health News:Anti Aging Clinic, the GTA’s Premier Provider of Anti Aging Treatments, Announces Deal on Units of Botox 2Health News:Pelican Water Supports Breast Cancer Awareness Month with Order Donations 2Health News:Rising Generic Drug Prices Affect Pharmacies, Insurers Alike, Reports AIS Newsletter 2Health News:Rising Generic Drug Prices Affect Pharmacies, Insurers Alike, Reports AIS Newsletter 3
... Addition of intravenous magnesium sulfate to standard emergency ... rather than enhance the effectiveness of treatment.// Dr. ... College of Medicine in the Bronx, New York, ... be helpful in the treatment of migraine headache ...
... in animal products raises the risk of breast cancer, ... suggested a link between a high fat diet, rich ... based in Chicago, USA, reveals that dietary differences might ... high where the proportion of daily calories from animal ...
... killer, accounting for one in four deaths, more than ... that the diversity of lung disease has yet to ... deal only in one disorder, chest physicians look after ... asthma, pneumonia, cystic fibrosis and sleep apnoea. There are ...
... complications in ovarian cancer. A gene implicated in inherited ovarian ... Up to 10 per cent of cases of ovarian cancer ... these cases, the woman usually has a strong family history ... developing, although it's not yet known in detail how it ...
... year worldwide if more people at high risk of having ... An analysis of nearly 300 clinical trials of aspirin and ... that aspirin reduces heart attacks and strokes in susceptible patients. ... from aspirin and anti-platelet therapy receive it. ,“This ...
... at Hopkins University, they have found a way to use ... system, surpassing an obstacle to certain forms of gene ... body's immune response to developing cancer vaccines to reducing the ... core of the blood system.// They can give rise to ...
Cached Medicine News:Health News:A new study surpasses Gene Therapy Hurdle 2
SATOs Neonatal Secure ID bands are your answer to comfort and safe patient identification of neonatal patients and newborns. Comfortable, yet durable, they display the patient and parent detail you d...
Platelet Aggregation Profiler...
... need to be a pain in the neck. ... longer handle to reduce the amount of arm ... with a conventional pipettor. The ergonomic design includes ... stand which enables the unit to be set ...
... all-new Assure Pro Blood Glucose Monitoring System ... of the Long-Term Care profession. More features ... strip release offer better convenience, safety, and ... test strip in the convenient top-of-the-meter port. ...
Medicine Products: